drugset / Trial / NCT04162340
CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies
Phase 1
Unknown
12 enrolled
iCell Gene Therapeutics
Peking University Shenzhen Hospital · collabiCAR Bio Therapeutics Ltd. · collab
NaSequentialOpen-labelTreatment
Summary
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD4 CAR T cells in patients with relapsed and/or refractory T cell lymphoma.
Timeline
- Start
- 2019-07-11
- Primary completion
- 2021-10
- Completion
- 2021-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD4 CAR T cells | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | CD4 CAR T cells | Cell therapy | 5e+06 cells/kg | Intravenous |